ERBB2 and cancer: This implicates that cell stemness controls the phenotypic transition between luminal A and HER2 positive breast cancer cells (Figure 7); and triple negative cells, though sharing similar cancer stemness with the HER2 positive subtype, represent a revolutionarily distinct disease from the other breast cancer subtypes that requires distinct therapeutic strategies for effective control.